|
|
||||||||
Department of Pharmacology, Yamagata University School of Medicine, Yamagata 990-9585, Japan
| |
ABSTRACT |
|---|
|
|
|---|
Endothelin-1 (ET-1)
increased cell shortening and Ca2+ transients over the
concentration of 3 × 10
11 M to 10
9 M
with EC50 of 8.3 × 10
11 M in rabbit
single ventricular myocytes. Thus ET-1 was approximately 60 times more
potent in single myocytes than in papillary muscles (EC50 = 5.1 × 10
9 M) of the same
species. In single myocytes, ET-1 at 10
8 M elicited an
inhibitory response that counteracted the facilitatory response: the
concentration-response curve (CRC) for ET-1 was bell shaped. The
ETA-receptor antagonist BQ-485 shifted CRC for ET-1 to the
right in parallel; however, the facilitatory response to
10
8 M ET-1 was markedly enhanced by BQ-485 and also by
the ETB antagonist BQ-788. The
ETA/ETB antagonist TAK-044 abolished the
ET-1-induced response. These findings indicate that the response to
ET-1 of single myocytes is different from that of papillary muscles in concentration dependence, characteristics of the response, and susceptibility to ET-receptor antagonists. Anomalous pharmacological characteristics of ET-1-induced response in rabbit papillary muscles may be due to integrated regulatory mechanisms that may involve also
various types of noncardiac cell in ventricular myocardium.
adult rabbit cardiomyocytes; cell shortening; Ca2+ transients; ETA receptor; ETB receptor
| |
INTRODUCTION |
|---|
|
|
|---|
ENDOTHELIN-1 (ET-1) is produced by various types of cardiovascular cells, including endothelial cells, vascular smooth muscle, and myocardial cells, and released into the circulating blood in a number of cardiovascular diseases such as congestive heart failure, myocardial infarction, atherosclerosis, and hypertension (15). It is, therefore, postulated that ET-1 may play a crucial role as an autocrine and/or paracrine regulator of cardiovascular function under various cardiovascular disorders (11, 13).
ET-1 elicits a pronounced positive inotropic effect (PIE) in mammalian cardiac muscle of most species, including rat, guinea pig, ferret, rabbit, and human (1, 18, 20, 21, 24). The PIE of ET-1 was most pronounced in the rabbit among mammalian species examined (24). The PIE of ET-1 in the rabbit papillary muscle showed atypical pharmacological characteristics that could not be explained by conventional classification of ET receptor subtype (12). ET-1 and ET-3 elicited the PIE essentially with equivalent efficacy and potency in the rabbit papillary muscle (24). Whereas the PIE of ET-3 was highly susceptible to the selective ETA-receptor antagonists (2), the main portion of the concentration-response curve (CRC) for the PIE of ET-1 was resistant to the conventional selective and nonselective ET-receptor antagonists, such as BQ-123, FR-139317, RES-701-1, IRL-1620, and PD-145065 (5, 12, 19). It is postulated therefore that divergent factors, including neurotransmitters and endogenous regulators such as cytokines, peptides and nitric oxide released from various types of cells in multicellular ventricular muscle preparations and/or the diffusion, which is a limiting factor due to endocardial endothelium in papillary muscle preparations, may contribute to the anomalous pharmacological characteristics of the inotropic response to ET-1 in the rabbit papillary muscle.
The present study was undertaken to characterize the inotropic response of single rabbit ventricular cardiomyocytes to ET-1 to elucidate whether the pharmacological characteristics differ from those in isolated rabbit papillary muscles (multicellular preparation). It was found that the inotropic response to ET-1 and the effectiveness of ET-receptor antagonists in single ventricular myocytes are quite different from those in multicellular preparation in respect to concentration dependence, mode of the response, and pharmacological characteristics.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
The current study involving experimental animals conforms to the institutional standards. The study was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Approval for the animal experiments was obtained from the Committee of Animal Experimentation, Yamagata University School of Medicine, before the experiments, and the study also was carried out in accordance with the Declaration of Helsinki.
Isolation of ventricular cardiomyocytes from rabbit heart. Single ventricular cardiomyocytes were isolated by the Langendorff procedure (7) with a slight modification. Briefly, adult male Japanese White rabbits (1.8-2.0 kg) were anesthetized with pentobarbital sodium (50 mg/kg iv) and given heparin (500 U/kg iv). The heart was quickly removed and immediately attached to an aortic cannula of a modified Langendorff apparatus for perfusion. The continuous retrograde perfusion with HEPES-Tyrode solution was started at a perfusion pressure of 80 cmH2O to washout the blood in the heart for approximately 1 min. The HEPES-Tyrode solution contained (in mM) 136.5 NaCl, 5.4 KCl, 0.53 MgCl2, 1.8 CaCl2, 0.33 NaH2PO4, 5.0 glucose, and 5.0 HEPES (pH 7.4 adjusted with NaOH). The solution was continuously gassed with 100% O2 at 37°C. The heart was then perfused with nominally Ca2+-free HEPES-Tyrode solution containing 0.6 mg/ml collagenase (Type II, Worthington Biochemical; Freehold, NJ) and 0.1 mg/ml protease (Type XIV, Sigma; St. Louis, MO). After ~20 min, when the heart became homogeneously soft, the enzymes were washed out for 1 min by perfusion with HEPES-Tyrode solution containing 0.2 mM CaCl2. The ventricles were then removed, cut into small pieces, placed in HEPES-Tyrode solution containing 0.2 mM CaCl2, and shaken gently on a shaker for easy dissociation of cells. The dispersed cells were filtered through a nylon-mesh (200 µm), and the cell suspension was rinsed several times with gradual increase of Ca2+ in HEPES-Tyrode solution in a stepwise manner up to 1.8 mM. Cells were finally suspended in HEPES-Tyrode solution containing 1.8 mM CaCl2 and kept at room temperature (25 ± 1°C) for 1 h or longer until they were used for experiments.
Indo 1 loading, cell superfusion, and electrical stimulation. Myocytes were loaded with an acetoxymethyl ester form of Ca2+ fluorescent probe, indo 1 (indo 1-AM), by incubating with 5 µM indo 1-AM solution in HEPES-Tyrode buffer for 1-4 min at room temperature. All of the following experimental steps were then carried out at room temperature (25 ± 1°C). After loading, the myocytes were layered onto HEPES-Tyrode buffer in a superfusion chamber on the stage of an inverted microscope (Diaphot TMD300, Nikon; Tokyo, Japan) equipped for simultaneous recording of cell length and indo 1 fluorescence, and allowed to settle down by gravity for 15 min. Continuous superfusion was then started with Krebs-Henseleit bicarbonate buffer at a rate of 2 ml/min, and 10 min later myocytes were stimulated electrically with square-wave pulses of 5 ms duration by bipolar platinum electrodes placed in the perfusion chamber at 0.5 Hz with voltage about 50% above the threshold. After an equilibration period of 40 min under electrical stimulation, the experimental protocols were carried out at room temperature. The cells used were rod shaped with clear transverse striations and had no blebs, no granulation, and no spontaneous contraction. Cells having only stable baseline contractile amplitude with a clear fluorescence ratio after electrical stimulation were used for the experiments. The bicarbonate buffer contained (in mM) 116.4 NaCl, 5.4 KCl, 0.8 MgSO4, 1.8 CaCl2, 1.0 NaH2PO4, 23.8 NaHCO3, 5.0 glucose; the buffer was continuously gassed with 95% O2-5% CO2 (pH 7.4).
Simultaneous measurements of cell shortening and indo 1 fluorescence ratio. Indo 1 fluorescence was excited with the light from a xenon lamp (150 W) with a wavelength of 355 nm, reflected by a 380-nm long-pass dichroic mirror and detected by means of a fluorescence spectrophotometer (CAM-230, Japan Spectroscopic; Tokyo, Japan). Excitation light was applied to the myocytes through a neutral density filter to minimize the photobleaching of indo 1. The emitted fluorescence was collected by an objective lens (CF Fluor DL40; Nikon) and after passing through a 380-nm long-pass dichroic mirror (Omega Optical; Brattleboro, VT), it was separated by a 580-nm long-pass dichroic mirror (Omega Optical). The fluorescence light was subsequently split by a 425-nm dichroic mirror to permit simultaneous measurements of both 405-nm and 500-nm wavelengths through bandpass filters, respectively, by the use of two separate photomultiplier tubes. The fluorescence ratio (405:500 nm) was used as an index of intracellular Ca2+ concentration ([Ca2+]i).
The cell length was monitored simultaneously with indo 1 fluorescence using red light (>620 nm) through the normal bright-field illumination optics of the microscope. The bright-field image of the cell was collected first by a 580-nm long-pass dichroic mirror. The bright-field image of a cell was projected onto a photodiode array of an edge detector (C6294-01, Hamamatsu Photonics; Hamamatsu, Japan) and scanned at every 5 ms. In the current study, an increase or decrease in cell shortening is considered to reflect qualitatively the PIE or negative inotropic effect (NIE) in isometric contractions, and is often referred to as PIE or NIE interchangeably without explanation.Data recording and analysis. Cell length and indo 1 fluorescence signals were collected in a Macintosh Computer (Power Macintosh 8100/100 AV, Apple Computer; Cuptertino, CA) by means of an A/D Converter (MP-100A, BIOPAC Systems; Santa Barbara, CA) at 200 Hz. Signals were analyzed after low-pass filtering (25-Hz cutoff frequency) and after averaging five successive signals.
Experimental values are presented as means ± SE. The EC50 value for ET-1 was obtained by graphic analysis of mean CRCs for both cell shortening and indo 1 ratio. For statistical analysis of multiple measurements obtained from a single preparation, we used one-way analysis of variance for repeated measures with Bonferroni test. The mean values between two groups were compared by Student's t-test for unpaired values. A P value <0.05 was judged to indicate a statistically significant difference.Study protocol for cell shortening and [Ca2+]i. After an equilibration period of 40 min, myocytes were exposed to the solution containing different concentrations of ET-1. ET-1 was administered either in a cumulative manner or by single administration. To determine the CRC for ET-1, the superfusate was switched to a solution that contained a higher concentration of ET-1 when the effects of the previous concentration reached a steady level. Where the influence of different ET antagonists were investigated, the antagonists were allowed to act for 20 min before the administration of the agonist and were present in the superfusate throughout the experiments. ET-1 was administered only once to each myocyte because the response to ET-1 was not reversed by washout. The cell length was monitored continuously throughout the experiments, whereas the indo 1 fluorescence was monitored only intermittently to reduce the potential photobleaching. Simultaneous recordings were made at the baseline state and in the presence of the agonist and/or antagonist when the response reached a steady level. The CRC for ET-1 determined by cumulative administration served as the control for examination of the influence of BQ-485, whereas the response to ET-1 administered by the single administration allowed us to investigate the time course of the response after the administration of ET-1 at various concentrations.
Papillary muscle preparation and experimental protocols. Details for experimental procedures used for isolated rabbit right ventricular papillary muscle preparation have been described previously (27). Briefly, two or three papillary muscles (<1 mm in diameter, ~5 mm in length) were isolated from the right ventricle of each rabbit and mounted vertically in 20-ml organ baths that contained Krebs-Henseleit solution (with 0.057 mM ascorbic acid and 0.027 mM EDTA-2Na). The solution was bubbled constantly with 95% O2-5% CO2 at 37°C (pH 7.4). Muscles were electrically stimulated by square-wave pulses of 5-ms duration at a voltage approximately 20% above the threshold, at a frequency of 1 Hz, through bipolar platinum electrodes. The developed tension was recorded on a thermal pen-writing oscillograph (Recti-Horiz-8K, NEC San-ei Instruments; Tokyo, Japan) by means of force-displacement transducers (Shinkoh UL 10 GR, Minebea; Nagano, Japan). The muscle was equilibrated for 60 min in drug-free solution. During the equilibration period, the muscles were stretch initially at a resting tension of 5 mN, and the length was later adjusted to give 90% of the maximal contractile force (Lmax). The concentration of ET-1 in the organ bath was increased in a cumulative manner in steps of 0.5 log units. When steady contractile force had been achieved, ET-1 was added to yield the next higher concentration. The effect of ET-1 was considered to be maximal when the successive concentrations failed to produce a further increase in contractile force.
Drugs and chemicals. The following drugs were used: ET-1 and ET-3 (Peptide Institute; Osaka, Japan), isoproterenol hydrochloride and protease (Type XIV, Sigma), collagenase (Type II, Worthington Biochemical), indo 1-AM (Dojin Chemical; Kumamoto, Japan), pentobarbital sodium (Tokyo Kasei Kogyo; Tokyo, Japan), BQ-485 and BQ-788 (Banyu Pharmaceuticals; Tsukuba, Japan), TAK-044 (Takeda Chemical Industries; Osaka, Japan). All other chemicals were of the highest analytic grade commercially available.
| |
RESULTS |
|---|
|
|
|---|
Concentration- and time-dependent effects of ET-1 on cell
shortening and indo 1 fluorescence ratio.
ET-1 applied by single administration to individual myocytes
significantly increased the cell shortening at 3 × 10
11 M and higher concentrations, and the indo 1 ratio
increased at 10
10 M and higher concentrations up to
10
9 M (Fig. 1). The
increase in both signals in response to ET-1 up to 10
9 M
developed gradually within 30 min; after the administration of ET-1 at
10
8 M, the steady level of cell shortening and indo 1 ratio was achieved within 15 min and remained stable up to 30 min.
Actual tracings of cell shortening and indo 1 ratio after the
administration of 10
9 M and 10
8 M are shown
in Fig. 2, A and B,
respectively.
|
|
9 M (Figs.
1, A-D, and 2A). After the
administration of ET-1 at 10
8 M the indo 1 ratio was not
increased significantly compared with the level before the
administration (107.7 ± 4.92%; n = 6). Instead a
significant decrease in indo 1 ratio (87.9 ± 1.81%) and cell shortening (76.9 ± 1.88%) (n = 6, each;
P < 0.05) was induced transiently (Figs. 1E
and 2B). The increase in cell shortening in response to ET-1
at 10
8 M (150.3 ± 6.91%, n = 6)
was significant compared with the control before the administration of
ET-1 but was less than that induced by 10
9 M (208.4 ± 13.2%, n = 5, P < 0.05, Fig. 1).
The CRC for increases in cell shortening and indo 1 ratio in response
to ET-1 was determined also by cumulative administration and summarized
data are presented as the control response in Fig. 3, A and B,
respectively. ET-1 elicited concentration-dependent increases in cell
shortening and indo 1 ratio by cumulative administration, and the
maximal response was achieved by ET-1 at 10
9 and 3 × 10
9 M (cell shortening, 179.6 ± 10.36%; indo 1 ratio, 150.4 ± 10.74%; n = 6, each). The
EC50 values for cell shortening and indo 1 ratio were
8.6 × 10
11 and 4.6 × 10
11 M,
respectively. The effects of ET-1 administered up to 3 × 10
9 M were not reversed by washout of ET-1 for 30 min.
|
Influence of ETA-receptor blockade by BQ-485 on ET-1-induced effects. Influence of BQ-485, a selective ETA-receptor antagonist, on the ET-1-induced cell shortening and indo 1 ratio was investigated in two series of experiments.
In first series, the influence of 10
7 M BQ-485 on the
CRCs for increases in cell shortening and indo 1 ratio induced by ET-1 was examined. BQ-485 at 10
7 M alone did not affect the
cell shortening or indo 1 ratio (data not shown). The CRCs for
increases in cell shortening and indo 1 ratio induced by ET-1 were
shifted to the right, essentially in parallel 49- and 41-fold in the
presence of 10
7 M BQ-485, when calculated graphically
from mean CRCs at the level of EC50 (4.2 × 10
9 M for cell shortening; 1.9 × 10
9
M for indo 1 ratio) in Fig. 3. The maximum responses achieved by ET-1
(3 × 10
8 M) in the presence of BQ-485 were
187.9 ± 11.37% for cell shortening and 157.9 ± 11.35% for
indo 1 ratio (Fig. 3, n = 4 each), which were not lower
than those in control myocytes.
In second series, the influence of BQ-485 (10
7 M) on the
effects of ET-1 by single administration was investigated. BQ-485 inhibited almost completely the effects of ET-1 at 10
10 M
(Fig. 4A) and
10
9 M (Fig. 4B). By contrast, the effects of
10
8 M ET-1 on cell shortening (208.4 ± 13.2%) and
indo 1 ratio (134.5 ± 10.3%) were significantly enhanced by the
presence of BQ-485 (P < 0.05, n = 5, Fig. 4C) 30 min after the administration. Transient negative
responses induced by 10
8 M ET-1 were abolished by BQ-485
(Fig. 4C).
|
Influence of ETB-receptor blockade by BQ-788 on
ET-1-induced effects.
In this series, we examined the influence of a novel selective
antagonist of ETB-receptors, BQ-788, on the ET-1-induced
cell shortening and indo 1 ratio. BQ-788 at 10
6 M did not
affect the baseline levels of cell shortening and indo 1 ratio (data
not shown). BQ-788 did not affect the responses induced by ET-1 at
10
10 M (Fig.
5A); it partially inhibited
the increases in cell shortening and indo 1 ratio induced by ET-1 at
10
9 M (Fig. 5B). The blockade of
ETB-receptors abolished the initial inhibitory action of
10
8 M ET-1, and it enhanced the increases in cell
shortening (175.6 ± 8.73%, P < 0.05) and indo 1 ratio (139.4 ± 3.59%, P < 0.05) induced by ET-1
at 10
8 M (n = 5 each), but the
enhancement of cell shortening by BQ-788 (Fig. 5C) was less
than that by BQ-485 (Fig. 4C).
|
Influence of combined ETA- and ETB-receptor
blockade by TAK-044.
To examine the influence of combined blockade of both ETA-
and ETB-receptors on the ET-1-induced responses, we
investigated the influence of TAK-044, a nonselective
ETA-/ETB-receptor antagonist, on cell
shortening and indo 1 ratio induced by ET-1 at 10
8 M. In
the presence of TAK-044 at 10
7 M, ET-1 at
10
8 M had no effects on the cell shortening and indo 1 ratio (Fig. 6).
|
Comparison of contractile response to ET-1 and ET-3 in myocytes and
papillary muscles.
Whereas ET-1 increased cell shortening in single myocytes and induced
PIE in isolated papillary muscles in a concentration-dependent manner,
the former was more sensitive than the latter (Fig.
7A). The EC50
values calculated graphically from mean CRCs in Fig. 7A were
8.3 × 10
11 M in myocytes and 5.1 × 10
9 M in papillary muscles. Myocytes were therefore
62-fold more sensitive to ET-1 than papillary muscles. By contrast, the
EC50 values for ET-3 were 1.1 × 10
8 M
in myocytes and 8.5 × 10
9 M papillary muscles.
There were no significant differences between the EC50
values derived for the effects of ET-3 on contractility of myocytes and
papillary muscles (Fig. 7B).
|
| |
DISCUSSION |
|---|
|
|
|---|
The important findings in the present study with ET-1- and
ET-receptor antagonists in single rabbit ventricular myocytes are that:
1) single myocytes were more than 60-fold more sensitive to
ET-1 in inducing the increase in cell shortening and Ca2+
transients than in producing the PIE in isolated rabbit papillary muscles; 2) in single myocytes a definite decrease in cell
shortening (NIE) was elicited by ET-1 at 10
8 M; and
3) the PIE and NIE of ET-1 were susceptible to the
ETA-receptor antagonist and also to the
ETB-receptor antagonist.
Mechanisms responsible for the difference in ET-1-induced
contractile response.
Several potential factors may be involved in the mechanism underlying
the difference in sensitivity to ET-1 between single myocytes and
papillary muscles. First, ET-1 might be able to access more
easily to the site of action in myocytes because of the absence of the
endocardial endothelium. Provided that the diffusion of ET-1 is a
limiting factor in papillary muscles, agents other than ET-1 might be
affected in a similar manner. However, the extent of difference in the
sensitivity of other agents was variable and not so great as that with
ET-1. For example, the EC50 values for the agents,
including ET-3 (myocytes vs. papillary muscles: 1.1 × 10
8 M vs. 8.5 × 10
9 M, Fig.
7B), angiotensin II (10
9 M vs. 1.1 × 10
8 M) and isoproterenol (1.70 × 10
9
M vs. 5.75 × 10
9 M) were not so greatly different
between myocytes and papillary muscles (3, 7, 8, 23, 27).
Furthermore, the treatment of papillary muscle with Triton X (0.1%),
which has been demonstrated to cause selective damages to endocardial
endothelial cells (15), did not appreciably affect the CRC
for ET-1 in papillary muscles (1, 3).
9 M induced the first phase [~20% of the maximal
response to isoproterenol (Isomax)] and at
10
9 M and higher ET-1 induced the second phase that
constituted the main portion of the CRC with the maximal response of
60% of Isomax (12, 24, 25). Because the first
phase was susceptible for ETA antagonists, whereas the
second phase was not antagonized but was rather enhanced by these
antagonists (5, 12, 19), we supposed that the first phase
in papillary muscles corresponds to the facilitatory response to ET-1
in myocytes and that the inhibitory substances may be released from
cardiac and/or noncardiac cells in papillary muscles, which might be
responsible for producing the low plateau of the first phase. According
to this postulate, we pharmacologically examined the influence of
potential endogenous inhibitory mechanisms by means of
selective inhibitors, including NG-monomethyl-L-arginine
(nitric oxide synthase inhibition), indomethacin (COX inhibition),
atropine, 8-phenyltheophylline (adenosine-receptor antagonist), AF-DX
116 BS (muscarinic M2-receptor antagonist), and pertussis
toxin (Gi protein inhibition) in preliminary
experiments. However, these inhibitors did not affect appreciably
the PIE of ET-1 in rabbit papillary muscles (3).
In summary, these findings indicate that: 1) the prominent
difference in the contractile response to ET-1 between myocytes and
papillary muscles was exerted selectively for ET-1; the difference occurs in ET-1 but not in ET-3, though they are structurally closely related and considered to act through an identical signal transduction pathway (5, 36); 2) the diffusion in papillary
muscles is not a limiting factor; 3) the difference in
experimental temperature does not play a crucial role; 4)
the mode of contraction, i.e., isotonic and isometric, may not be
essential; 5) difference in pH or presence of hypoxic core
in papillary muscles does not play an important role; and 6)
modulation by known cardiac inhibitory mechanisms examined is not
responsible for the difference. Because the findings in the current
study showed that the factors mentioned above may not play a key role,
other factors, including the experimental procedure to prepare single
myocytes and regulation of receptor sites on which ET-1 acts, may be
responsible for producing the difference in the potency of ET-1 between
myocytes and papillary muscles.
Cellular mechanisms for contractile regulation induced by ET-1. The PIE of ET-1 is due to increases in both the amplitude of Ca2+ transients and myofilament Ca2+ sensitivity (7, 31). The ET-1-induced increase in Ca2+ transients has been shown to be highly susceptible to the inhibition of Na+/Ca2+ exchanger induced by KB-R7943 (35), indicating that secondary activation of the exchanger subsequent to stimulation of Na+/H+ exchanger may play a crucial role in the ET-1-induced increase in Ca2+ mobilization (14). The ET-1-induced facilitation of L-type Ca2+ current may also contribute to the increase in contractile force and Ca2+ transients in rabbit ventricular myocardium (27, 33). Thus the increase in the amplitude of Ca2+ transients induced by ET-1 may be due to synergistic contribution of activation of L-type Ca2+ channels (27, 33) and Na+/Ca2+ exchanger (35), whereas activation of Na+/H+ exchanger may contribute to both the increase in Ca2+ transients and myofilament Ca2+ sensitivity induced by ET-1 in rabbit ventricular myocardium (30, 35). Although it is unknown how these mechanisms differ in myocytes and papillary muscles, it has been shown that angiotensin II that shares the signal transduction process with ET-1 to lead to an increase in Ca2+ transients and myofilament Ca2+ sensitivity elicited an identical action in indo 1 loaded myocytes (8) and aequorin-loaded papillary muscles (32).
Negative inotropic effect of ET-1.
In single rabbit ventricular myocytes, the PIE of ET-1 at
10
8 M was counteracted by a pronounced secondary NIE that
is responsible for the bell-shaped CRC of ET-1 in myocytes. The
secondary NIE is not due to Ca2+ overload because it was
associated with a suppression of the amplitude of Ca2+
transients (Fig. 1E). However, it is likely that the
Ca2+ transient amplitude could still be suppressed under
conditions of Ca2+ overload when spontaneous
Ca2+ release from the sarcoplasmic reticulum (SR) could
reduce the SR Ca2+ available for release in response to
electrical stimulation. However, we have never observed any
experimental evidence for diastolic Ca2+ release, such as
an increase in diastolic levels of [Ca2+]i
during the induction of NIE by ET-1. Considering that indo 1 is highly
sensitive to detecting the alteration of the diastolic [Ca2+]i level, spontaneous Ca2+
release during diastole may be excluded.
8 M (Figs. 4 and
5), both subtypes are considered to be involved in the NIE. The
observation that the selective ETA-receptor antagonist BQ-485 produced a parallel shift of the CRC for PIE of ET-1 indicates that the bell-shape CRC may be shifted to the right without altering the shape of the CRC. Although the Ca2+ transient amplitude
was similar during the blockade of ETA and ETB
receptors at 10
8 M ET-1, the percentage of cell
shortening was higher with ETA blockade than with
ETB blockade, an indication that each subtype may trigger
different signaling pathways in addition to NIE mediated by both
subtypes (Figs. 3 and 4). Although it is not clear whether the
ETB blockade has a different effect on myofilament
Ca2+ sensitivity than ETA blockade, we have
observed in rabbit ventricular myocytes that the dual effect of ET-1 on
calcium current (ICa) was abolished by the
ETA antagonist FR-139317, whereas the inhibitory component
of the ET-1-induced ICa response was selectively
antagonized by the ETB antagonist BQ-788, which supports
the postulate that ETA and ETB receptors may
activate different signaling pathways in rabbit ventricular myocardium.
The secondary NIE may be exerted by receptor-mediated suppression of
Ca2+ mobilization because ET-receptor antagonists abolished
both the decreases in cell shortening and Ca2+ transients.
The secondary NIE of ET-1 is also induced in isolated rabbit papillary
muscles, but the extent is much less compared with single myocytes
(refer to Fig. 4 of Ref. 24 and Fig. 3 of Ref.
25). Furthermore, the second phase of the PIE of ET-1 was
enhanced by selective antagonists of ETA receptors
(5, 12, 19, 24), supporting the view that ET-1 causes the
NIE in papillary muscles.
Patch-clamp experiments were carried out in single rabbit ventricular
myocytes to elucidate the role of ICa in
regulation of Ca2+ transients induced by ET-1
(33). ET-1 at 10
8 M elicited a biphasic
effect, i.e., a long-lasting increase in ICa
subsequent to a transient decrease (32). Whereas the
decrease in ICa was inhibited by antagonists of
ETA (FR-139317) or ETB (BQ-788) receptors, the
increase in ICa induced by ET-1 was antagonized only by FR-139317 (33). Although the detailed analysis of
the relationship between the concentration of ET-1- and ET-receptor antagonists was not carried out, it appears to be evident that the
ET-1-induced inhibition of ICa is partially
responsible for the decrease in Ca2+ transients, which
leads to NIE in rabbit ventricular myocytes. Activation of protein
kinase C (PKC) by tumor-promoting phorbol esters has been shown to lead
to either PIE or NIE depending on the concentration applied and species
of animals employed (4, 9, 26). In this context
pHi altered by PKC via Na+/H+
exchanger might also be involved in the biphasic inotropic response to
ET-1 (13, 14). Recently, we have examined the influence of
the PKC inhibitor chelerythrine on the ET-1-induced biphasic response
and found that chelerythrine inhibited the PIE leaving the NIE
unaltered, an indication that the excessive PKC activation is unlikely
to be responsible for the NIE (29).
In conclusion, contractile regulation by ET-1 in rabbit ventricular
myocytes is quite different from that in papillary muscle. ET-1 was
much more potent in myocytes than in papillary muscles inducing the
contractile response. The effects of ET-1 on Ca2+
transients and cell shortening in single myocytes were effectively antagonized by the selective ETA-receptor antagonist BQ-485
and partially by the ETB-receptor antagonist BQ-788. These
observations are essentially similar to those in other species
including humans, rats, and guinea pigs (11, 16, 17, 21,
28). These findings imply that the anomalous pharmacological
characteristics of the ET-1-induced PIE in rabbit papillary muscles
(3, 12, 19) is not due to atypical nature of ET receptor
subtypes in the rabbit heart. The integrated regulatory mechanisms in
the multicellular preparation including noncardiac cells may be
responsible for the resistance to ETA-receptor antagonists
of the ET-1-induced PIE in rabbit papillary muscles.
| |
ACKNOWLEDGEMENTS |
|---|
We thank T. Watanabe for sharing preparations of rabbit ventricular cardiomyocytes in some of the present experiments, and H. Sugawara for valuable technical advice in carrying out the experiments. We also thank Banyu Pharmaceutical (Tsukuba, Japan) for a generous supply of BQ-485 and BQ-788 and Takeda Chemical Industries (Osaka, Japan) for providing TAK-044.
| |
FOOTNOTES |
|---|
This work was supported in part by Grants-in-Aid 11470021 and 11557203 for Scientific Research (B) from the Ministry of Education, Science, Sports and Culture (Japan) and by the Research Grant for Cardiovascular Disease (11C-1) from the Ministry of Health and Welfare (Japan).
Present address of M. A. H. Talukder: Dept. of Pharmacology, The Brody School of Medicine, East Carolina University, Greenville, NC 27858.
Address for reprint requests and other correspondence: M. Endoh, Dept. of Pharmacology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan (E-mail: mendou{at}med.id.yamagata-u.ac.jp).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 30 October 2000; accepted in final form 12 March 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Endoh, M.
The effects of various drugs on the myocardial inotropic response.
Gen Pharmacol
26:
1-31,
1995[Web of Science][Medline].
2.
Endoh, M,
Fujita S,
Yang HT,
Talukder MA,
Maruya J,
and
Norota I.
Endothelin: receptor subtypes, signal transduction, regulation of Ca2+ transients and contractility in rabbit ventricular myocardium.
Life Sci
62:
1485-1489,
1998[Web of Science][Medline].
3.
Endoh, M,
Maruya J,
Norota I,
Yang HT,
Talukder AMH,
Watanabe T,
and
Sakurai K.
Cardiac effects of endothelin: difference between single myocytes and intact ventricular myocardium.
Cur Topics Pharmacol
4:
293-300,
1998.
4.
Endoh, M,
Norota I,
Takanashi M,
and
Kasai H.
Inotropic effects of staurosporine, NA 0345 and H-7, protein kinase C inhibitors, on rabbit ventricular myocardium: selective inhibition of the positive inotropic effect mediated by
1-adrenoceptors.
Jpn J Pharmacol
63:
17-26,
1993[Medline].
5.
Endoh, M,
Norota I,
Yang HT,
Fujita S,
and
Takanashi M.
The positive inotropic effect and the hydrolysis of phosphoinositide induced by endothelin-3 in rabbit ventricular myocardium: inhibition by a selective antagonist of ETA receptors, FR139317.
J Pharmacol Exp Ther
277:
61-70,
1996
6.
Endoh, M,
Wagner J,
and
Schümann HJ.
Influence of temperature on the positive inotropic effects mediated by
- and
-adrenoceptors in the isolated rabbit papillary muscle.
Naunyn Schmiedebergs Arch Pharmacol
287:
61-72,
1975[Web of Science][Medline].
7.
Fujita, S,
and
Endoh M.
Effects of endothelin-1 on [Ca2+]i-shortening trajectory and Ca2+ sensitivity in rabbit single ventricular cardiomyocytes loaded with indo 1-AM: comparison with the effects of phenylephrine and angiotensin II.
J Card Fail
2:
S45-S57,
1996[Medline].
8.
Fujita, S,
and
Endoh M.
Influence of a Na+H+ exchange inhibitor ethylisopropylamiloride, a Na+/Ca2+ exchange inhibitor KB-R7943 and their combination on the increases in contractility and Ca2+ transient induced by angiotensin II in isolated adult rabbit ventricular myocytes.
Naunyn Schmiedebergs Arch Pharmacol
360:
575-584,
1999[Web of Science][Medline].
9.
Gwathmey, JK,
and
Hajjar RJ.
Effect of protein kinase C activation on sarcoplasmic reticulum function and apparent myofibrillar Ca2+ sensitivity in intact and skinned muscles from normal and diseased human myocardium.
Circ Res
67:
744-752,
1990
10.
Ikenouchi, H,
Barry WH,
Bridge JH,
Weinberg EO,
Apstein CS,
and
Lorell BH.
Effects of angiotensin II on intracellular Ca2+ and pH in isolated beating rabbit hearts and myocytes loaded with the indicator indo 1.
J Physiol
480:
203-215,
1994
11.
Ishikawa, T,
Yanagisawa M,
Kimura S,
Goto K,
and
Masaki T.
Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria.
Am J Physiol Heart Circ Physiol
255:
H970-H973,
1988
12.
Kasai, H,
Takanashi M,
Takasaki C,
and
Endoh M.
Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart.
Am J Physiol Heart Circ Physiol
266:
H2220-H2228,
1994
13.
Kohmoto, O,
Ikenouchi H,
Hirata Y,
Momomura S,
Serizawa T,
and
Barry WH.
Variable effects of endothelin-1 on [Ca2+]i transients, pHi, and contraction in ventricular myocytes.
Am J Physiol Heart Circ Physiol
265:
H793-H800,
1993
14.
Krämer, BK,
Smith TW,
and
Kelly RA.
Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na+-H+ exchanger.
Circ Res
68:
269-279,
1991
15.
Meulemans, AL,
Andries LJ,
and
Brutsaert DL.
Does endocardial endothelium mediate positive inotropic response to angiotensin I and angiotensin II?
Circ Res
66:
1591-1601,
1990
16.
Modesti, PA,
Vanni S,
Paniccia R,
Bandinelli B,
Bertolozzi I,
Polidori G,
Sani G,
and
Neri Serneri GG.
Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes.
J Cardiovasc Pharmacol
34:
333-339,
1999[Web of Science][Medline].
17.
Molenaar, P,
O'Reilly G,
Sharkey A,
Kuc RE,
Harding DP,
Plumpton C,
Gresham GA,
and
Davenport AP.
Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.
Circ Res
72:
526-538,
1993
18.
Moravec, CS,
Reynolds EE,
Stewart RW,
and
Bond M.
Endothelin is a positive inotropic agent in human and rat heart in vitro.
Biochem Biophys Res Commun
159:
14-18,
1989[Web of Science][Medline].
19.
Norota, I,
and
Endoh M.
Pharmacological characteristics of endothelin receptors in the rabbit ventricular myocardium: the nonselective endothelin receptor antagonist PD 145065 antagonizes the positive inotropic effect of endothelin-3 but not of endothelin-1.
Mol Cell Biochem
161:
67-74,
1996.
20.
Qiu, Z,
Wang J,
Perreault CL,
Meuse AJ,
Grossman W,
and
Morgan JP.
Effects of endothelin on intracellular Ca2+ and contractility in single ventricular myocytes from the ferret and human.
Eur J Pharmacol
214:
293-296,
1992[Web of Science][Medline].
21.
Rubanyi, GM,
and
Polokoff MA.
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.
Pharmacol Rev
46:
325-415,
1994[Web of Science][Medline].
22.
Sato, S,
Talukder MA,
Sugawara H,
Sawada H,
and
Endoh M.
Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo 1-loaded single ventricular cardiomyocytes of the rabbit.
J Mol Cell Cardiol
30:
1115-1128,
1998[Web of Science][Medline].
23.
Sugawara, H,
Sakurai K,
Atsumi H,
Nakada S,
Tomoike H,
and
Endoh M.
Differential alteration of cardiotonic effects of EMD 57033 and
-adrenoceptor agonists in volume-overload rabbit ventricular myocytes.
J Card Fail
6:
338-349,
2000[Web of Science][Medline].
24.
Takanashi, M,
and
Endoh M.
Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium.
Am J Physiol Heart Circ Physiol
261:
H611-H619,
1991
25.
Takanashi, M,
and
Endoh M.
Concentration- and time-dependence of phosphoinositide hydrolysis induced by endothelin-1 in relation to the positive inotropic effect in the rabbit ventricular myocardium.
J Pharmacol Exp Ther
262:
1189-1194,
1992
26.
Talukder, MAH,
and
Endoh M.
Differential effects of protein kinase C activators and inhibitors on
- and
-adrenoceptor-mediated positive inotropic effect in isolated rabbit papillary muscle.
J Cardiovasc Pharmacol Ther
2:
159-170,
1997.
27.
Talukder, MAH,
and
Endoh M.
Pharmacological differentiation of synergistic contribution of L-type Ca2+ channels and Na+/H+ exchange to the positive inotropic effect of phenylephrine, endothelin-3 and angiotensin II in the rabbit ventricular myocardium.
Naunyn Schmiedebergs Arch Pharmacol
355:
87-96,
1997[Web of Science][Medline].
28.
Vogelsang, M,
Broede-Sitz A,
Schafer E,
Zerkowski HR,
and
Brodde OE.
Endothelin ETA-receptors couple to inositol phosphate formation and inhibition of adenylate cyclase in human right atrium.
J Cardiovasc Pharmacol
23:
344-347,
1994[Web of Science][Medline].
29.
Wang H and Endoh M. Chelerythrine and genistein inhibit the
endothelin-1-induced increase in myofilament Ca2+
sensitivity in rabbit ventricular myocytes. Eur J Pharmacol
2001. In press.
30.
Wang, H,
Sakurai K,
and
Endoh M.
Pharmacological analysis by HOE642 and KB-R9032 of the role of Na+/H+ exchange in the endothelin-1-induced Ca2+ signaling in rabbit ventricular myocytes.
Br J Pharmacol
131:
638-644,
2000[Web of Science][Medline].
31.
Wang, JX,
Paik G,
and
Morgan JP.
Endothelin 1 enhances myofilament Ca2+ responsiveness in aequorin-loaded ferret myocardium.
Circ Res
69:
582-589,
1991
32.
Watanabe, A,
and
Endoh M.
Relationship between the increase in Ca2+ transient and contractile force induced by angiotensin II in aequorin-loaded rabbit ventricular myocardium.
Cardiovasc Res
37:
524-531,
1998
33.
Watanabe, T,
and
Endoh M.
Characterization of the endothelin-1-induced regulation of L-type Ca2+ current in rabbit ventricular myocytes.
Naunyn Schmiedebergs Arch Pharmacol
360:
654-664,
1999[Web of Science][Medline].
34.
Watanabe, T,
Kusumoto K,
Kitayoshi T,
and
Shimamoto N.
Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of L-type calcium channels.
J Cardiovasc Pharmacol
13:
S108-S111,
1989.
35.
Yang, HT,
Sakurai K,
Sugawara H,
Watanabe T,
Norota I,
and
Endoh M.
Role of Na+/Ca2+ exchange in endothelin-1-induced increases in Ca2+ transient and contractility in rabbit ventricular myocytes: pharmacological analysis with KB-R7943.
Br J Pharmacol
126:
1785-1795,
1999[Web of Science][Medline].
36.
Yang, HT,
Zhu Y,
and
Endoh M.
Species-dependent differences in inotropic effects and phosphoinositide hydrolysis induced by endothelin-3 in mammalian ventricular myocardium.
Br J Pharmacol
120:
1497-1504,
1997[Web of Science][Medline].
This article has been cited by other articles:
![]() |
T. L. Domeier, A. V. Zima, J. T. Maxwell, S. Huke, G. A. Mignery, and L. A. Blatter IP3 receptor-dependent Ca2+ release modulates excitation-contraction coupling in rabbit ventricular myocytes Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H596 - H604. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Leite-Moreira and C. Bras-Silva Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1194 - H1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Brutsaert Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile Performance, and Rhythmicity Physiol Rev, January 1, 2003; 83(1): 59 - 115. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |